Status:
UNKNOWN
Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis
Lead Sponsor:
University of Cape Town
Collaborating Sponsors:
Partners in Health
Epicentre
Conditions:
Multi-drug Resistant Tuberculosis
Eligibility:
All Genders
15-99 years
Brief Summary
PandrTB is a study of the pharmacokinetics(PK) and pharmacodynamics(PD) of bedaquiline, delamanid, clofazimine, linezolid, moxifloxacin, levofloxacin and pyrazinamide used in novel combinations to tre...
Detailed Description
PandrTB is an observational study nested in the endTB (a randomized study that will evaluate five 9-month, injectable-sparing regimens) and endTB-Q (and RCT evaluating a 4 drug oral regimen given for ...
Eligibility Criteria
Inclusion
- All patients enrolled to the experimental arms of the endTB study and provide their written informed consent to participate in the PandrTB study.
Exclusion
- \-
Key Trial Info
Start Date :
January 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 30 2023
Estimated Enrollment :
625 Patients enrolled
Trial Details
Trial ID
NCT03827811
Start Date
January 30 2020
End Date
April 30 2023
Last Update
November 4 2022
Active Locations (7)
Enter a location and click search to find clinical trials sorted by distance.
1
National Scientific Center of Phthisiopulmonology
Almaty, Kazakhstan
2
Partners in Health Lesotho House 233 Corner Lancers and Caldwell Roads
Maseru, Lesotho, 100
3
Indus Hospital
Karachi, Pakistan
4
Peru-1
Lima, Peru